Background: Gender differences in life expectancy result in a higher proportion of women in the older population. This causes a female preponderance among elderly patients with ischaemic stroke. On the other hand, upper age limits are frequently used in clinical trials, in part due to safety reasons and logistical concerns. In this study, we model how applying upper age limits will lead to a gender disparity in stroke trials, favouring the inclusion of men rather than women. Methods: We analyzed a prospective hospital-based stroke registry covering the entire Federal State of Hesse, Germany. All cases with admission between 2003 and 2005 and a final diagnosis of ischaemic stroke (ICD10:I63) were selected. For various upper age limits (70, 75, 80, 85 and 90 years), we calculated the proportion of men and women excluded based on their age when applying the respective age span to the study population. Results: A total of 34,754 patients were analyzed, and 17,748 (51%) hereof were women. Their mean age was 73.6 ± 12.1 years. The women were older than the men (76.8 ± 11.7 years vs. 70.2 ± 11.7 years; p < 0.001). All upper age limits provoked a significant gender disparity by leaving a higher proportion of female than male patients outside the admissible range. In particular, selecting 80 years as the upper age cut-off excluded 19% of all male patients but 44% of all female patients (p < 0.001). Conclusions: Setting an upper age limit for ischaemic stroke trials is likely not to be gender neutral but withholds a higher proportion of female than male patients from study participation. Investigators should be aware of such gender imbalances, which may involuntarily be transferred into routine clinical practice.

Keywords:
Age, Ischaemic stroke, Clinical trials, Gender
This content is only available via PDF.
© 2010 S. Karger AG, Basel
2010
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.